Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug

Stock Track

Apr 13

IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.

The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.

Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1197511698"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197511698\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197511698?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-13 18:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197511698","market":"nz","top_or_hot":-1,"title":"Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug","media":"Stock Track","content":"<p>IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.</p><p>The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.</p><p>Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-13 18:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.</p><p>The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.</p><p>Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDYA","symbol_name":"IDEAYA Biosciences","start_time":0,"source_url":"","article_id":"1197511698","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197511698","pubTimestamp":1776076722,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.The oncology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDYA":"IDEAYA Biosciences"},"translate_title":"个股追踪|眼癌药物2/3期试验结果积极IDEAYA Biosciences盘前大涨31.15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1},"content_text":"IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}